Adma Biologics (ADMA) Retained Earnings (2011 - 2025)

Adma Biologics has reported Retained Earnings for 14 years, with the latest figure at -$161.7 million in Q4 2025.

• For the quarter ending Q4 2025, Retained Earnings rose 47.61% year-over-year to -$161.7 million; the trailing twelve-month figure through Dec 2025 stood at -$161.7 million (up 47.61% YoY), and the FY2025 full-year result was -$161.7 million, up 47.61% from the prior year.
• Retained Earnings for Q4 2025 stood at -$161.7 million, up from -$211.0 million in the prior quarter.
• The five-year high for Retained Earnings was -$161.7 million in Q4 2025, with the low at -$506.3 million in Q4 2023.
• Historically, Retained Earnings has averaged -$396.1 million across 5 years, with a median of -$428.8 million in 2022.
• Annual changes were most pronounced in 2021 — Retained Earnings retreated 26.37% — and 2025, when it soared 49.81%.
• Adma Biologics' Retained Earnings stood at -$412.1 million in 2021, then dropped by 15.99% to -$478.0 million in 2022, then retreated by 5.91% to -$506.3 million in 2023, then jumped by 39.05% to -$308.6 million in 2024, then soared by 47.61% to -$161.7 million in 2025.
• The last three Retained Earnings figures came in at -$161.7 million (Q4 2025), -$211.0 million (Q3 2025), and -$247.5 million (Q2 2025), per Business Quant data.